Skip navigation

A trial comparing gemcitabine alone with gemcitabine and capecitabine together after surgery to remove cancer of the pancreas (ESPAC-4)

This trial is looking at gemcitabine on its own or alongside another drug called capecitabine after surgery for pancreatic cancer. The trial is funded by Cancer Research UK.

Cancer of the pancreas is very difficult to treat. If possible, doctors use surgery to remove the cancer. But even if you have the cancer removed, there is a risk that it will come back. Some trials have shown that having chemotherapy after surgery helps to stop or delay the cancer coming back.

Gemcitabine is a chemotherapy drug that doctors often use to treat cancer of the pancreas. In this trial, the researchers are looking at adding another drug called capecitabine.

The aims of the trial are

  • To see if gemcitabine combined with capecitabine works better than gemcitabine alone after surgery for pancreatic cancer
  • To learn more about the side effects of treatment

Recruitment

Start 13/10/2008
End 30/09/2014

Phase

Phase 3

Who can enter

You can enter this trial if you

  • Have ductal adenocarcinoma of the pancreas
  • Have had surgery to remove the cancer in the last 12 weeks, and your surgeon was able to remove both the cancer and a border of tissue around it
  • Have recovered from your surgery and are well enough to take part in the trial
  • Have satisfactory blood test results
  • Are at least 18 years old
  • Are willing to use a reliable form of contraception if there is any chance you or your partner could become pregnant

You cannot enter this trial if you

Trial design

This is an international trial that will recruit 1,080 people from around the world. It is a randomised trial. You will be put into one of 2 treatment groups by a computer. Neither you nor your doctors will be able to decide which group you are in.

Everybody taking part will have chemotherapy in 28 day (4 week) cycles of treatment. You have up to 6 cycles of treatment, lasting nearly 6 months (24 weeks) in all.

If you are in group 1, you have gemcitabine through a drip into a vein on days 1, 8 and 15 of each treatment cycle.

If you are in group 2, you have gemcitabine in the same way as group 1, and you have capecitabine tablets to take at home on days 1 to 21 of each treatment cycle.

The doctors will ask you to fill in a questionnaire at the beginning of the trial, after 3, 6, 12, 18 and 24 months, and then once a year for up to 5 years. The questionnaire will ask about how you are feeling and any side effects you have. This is called a quality of life study.

The researchers will ask your permission to take a number of blood and urine samples when you go to your hospital appointments. This is so that they can learn more about pancreatic cancer. They will also ask your permission to take samples of both normal tissue and cancer cells during your surgery. And to collect more blood and urine samples on the day of the operation.

All samples will be stored safely and may be used in the future, but only for research purposes. If you do not want to give these extra samples for research, you don’t have to. You can still take part in the trial.

Hospital visits

Before you start treatment, you will go to the hospital to see the doctors and have some tests. These include

  • Physical examination
  • CT scan
  • Heart trace (ECG)
  • Blood tests

You will go to hospital 3 times in each cycle of treatment to have gemcitabine. You have this in the outpatient department and it takes about 2 hours each time. You will have regular blood tests during your course of treatment.

After you finish your treatment, you will see the doctors every 3 months for up to 5 years. You will have a blood test at each visit.

Side effects

The most common side effects of gemcitabine and capecitabine include

There is more information about the side effects of gemcitabine and capecitabine on CancerHelp UK.

Location of trial

For more information

The Information Nurses
Cancer Research UK
Angel Building
407 St John Street
London
EC1V 4AD

Tel: 0808 800 4040
Email: cancer.info@cancer.org.uk

Please note: we cannot help you to join a specific trial. Unless we state otherwise in this trial summary, you must go through your own doctor.

Chief Investigator

Professor John Neoptolemos

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
National Cancer Research Network (NCRN)
Royal Liverpool and Broadgreen University Hospital NHS Trust
University of Liverpool